Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
BioAge Labs Inc (NASDAQ: BIOA) closed the day trading at $18.81 down -0.48% from the previous closing price of $18.9. In other words, the price has decreased by -$0.48 from its previous closing price. On the day, 0.95 million shares were traded. BIOA stock price reached its highest trading level at $18.96 during the session, while it also had its lowest trading level at $18.37.
Ratios:
For a better understanding of BIOA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.87 and its Current Ratio is at 11.87. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On October 22, 2025, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 13 ’26 when GOLDSTEIN DOV A MD sold 27,000 shares for $19.70 per share. The transaction valued at 531,828 led to the insider holds 22,408 shares of the business.
Fortney Kristen sold 233,107 shares of BIOA for $4,223,036 on Jan 13 ’26. The Chief Executive Officer now owns 976,949 shares after completing the transaction at $18.12 per share. On Jan 13 ’26, another insider, Fortney Kristen, who serves as the 10% Owner of the company, bought 233,107 shares for $18.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIOA now has a Market Capitalization of 785363968 and an Enterprise Value of 395788256. For the stock, the TTM Price-to-Sale (P/S) ratio is 113.92 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 66.89 whereas that against EBITDA is -4.421.
Stock Price History:
The Beta on a monthly basis for BIOA is 1.35, which has changed by 2.5027933 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, BIOA has reached a high of $24.00, while it has fallen to a 52-week low of $2.88. The 50-Day Moving Average of the stock is 45.63%, while the 200-Day Moving Average is calculated to be 175.44%.
Shares Statistics:
Over the past 3-months, BIOA traded about 638.00K shares per day on average, while over the past 10 days, BIOA traded about 1249530 shares per day. A total of 35.85M shares are outstanding, with a floating share count of 22.74M. Insiders hold about 36.58% of the company’s shares, while institutions hold 35.56% stake in the company. Shares short for BIOA as of 1767139200 were 596127 with a Short Ratio of 0.93, compared to 1764288000 on 502999. Therefore, it implies a Short% of Shares Outstanding of 596127 and a Short% of Float of 1.95.
Earnings Estimates
. The current market rating for BioAge Labs Inc (BIOA) reflects the collective analysis of 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.55 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$2.06 and -$2.27 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$2.79, with 3.0 analysts recommending between -$2.65 and -$2.91.
